Symptomatic cytomegalovirus (CMV*) infection occurs in 8%, 29%, 25%, and 39% of kidney,
liver, heart, and heartlung transplant recipients, respectively (1). CMV is transmitted to …

We investigated relationships between cytomegalovirus (CMV) seropairing and CMV
prophylaxis on graft outcome in recipients of solid organ transplants. Transplants carried out …

The past 1–2 years have seen major developments in the area of CMV management in
transplant recipients. Expanding diagnostic and therapeutic capabilities provide a …

Cytomegalovirus (CMV) continues to be a cause of substantial morbidity and death after
solid-organ transplantation. There are 3 major consequences of CMV infection: CMV …

Abstract Cytomegalovirus (CMV)-seronegative recipients (R-) of a liver transplant from CMV-
positive donors (D+) are at high risk for developing late CMV disease after discontinuation of …

Late-onset cytomegalovirus disease in patients with solid or... : Current Opinion in Infectious
Diseases Late-onset cytomegalovirus disease in patients with solid organ transplant : Current …

Efforts to prevent relapsed cytomegalovirus (CMV) disease among solid organ transplant
(SOT) recipients present clinical challenges. Historically, SOT recipients treated with short …

Prolonging cytomegalovirus (CMV) prophylaxis in CMV seronegative recipients of a kidney
from CMV seropositive donor (D+/R–) may reduce the incidence of late infections. We …

Cytomegalovirus (CMV) is the most common viral infection during the post-transplant period,
and it is one of the major causes of morbidity and mortality in kidney transplantation. In this …

Clinical practice guidelines recommend antiviral prophylaxis to cytomegalovirus (CMV)
donor‐positive/recipient‐negative (D+/R−) liver transplant recipients. We assessed the …